When federal regulators last week approved Digene Corp.'s cervical cancer test as a primary screening tool for women over 30, they catapulted what had been a follow-up test into direct competition ...

Sales of Digene Corp.'s two-in-one test for cervical cancer jumped 66 percent in its fiscal first quarter, sending the biotechnology company's revenue and earnings higher. For the quarter ended Sept.

Digene has struck a deal with Austin-based Asuragen to sell a diagnostic test under development for cystic fibrosis. Asuragen is seeking regulatory approval for the test, which would be the second on ...

NEW YORK, Jan 12 (Reuters) - Digene Corp's new chief executive officer said on Friday the company could not afford to remain "a one-product company" and would aim to disclose a strategy of moving ...

CHICAGO, Jan 12 (Reuters) - Third Wave Technologies Inc. said its tests to diagnose the human papillomavirus do not infringe on rival Digene Corp.'s patent as alleged in a lawsuit filed on Thursday.